Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Comirnaty Original/Omicron BA.1 TM
Active ingredients: tozinameran + riltozinameran
What it is used for
COMIRNATY ORIGINAL/OMICRON BA.1 Vaccine has provisional approval for the indication below: As a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 18 years of age and older. The use of this vaccine should be in accordance with official recommendations. The decision has been made on the basis of short term immunogenicity and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.
How to take it
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
- Store between minus 60 - minus 90 degrees
- Protect from Light
- See Product information for shelf life
- Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
white to off-white frozen suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient tozinameran + riltozinameran
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
Top results
COVID-19 vaccines: Frequently asked questions (FAQs) | NCIRS
COVID-19 vaccines: Frequently asked questions (FAQs) COVID-19 Australian Immunisation Handbook COVID-19 vaccines Immunisation coverage data and reports Education and training History of immunisation Immunisation schedules National and international resources NCIRS fact sheets, FAQs and other resources COVID-19 DTPa-HB-IPV-Hib vaccine (Vaxelis® and Infanrix hexa®) Haemophilus influenzae type b (Hib) Hepatitis B Human papillomavirus Influenza Japanese encephalitis Measles Measles vaccination catch-up guide Meningococcal Mpox (formerly known as monkeypox) Mumps Pertussis Pneumococcal Poliomyelitis Respiratory syncytial virus (RSV) Rotavirus Rubella Varicella-zoster (chickenpox) Zoster (shingles) Injection site reactions Vaccine components Vaccines for Australian adults Vaccinations during pregnancy NCIRS webinar series Patient communication resources Specialist immunisation services SKAI - supporting health professionals NCIRS newsletters Vaccine safety COVID-19 Australian Immunisation Handbook COVID-19 vaccines Immunisation coverage data and reports Education and training History of immunisation Immunisation schedules National and international resources NCIRS fact sheets, FAQs and other resources COVID-19 DTPa-HB-IPV-Hib vaccine (Vaxelis® and Infanrix hexa®) Haemophilus influenzae type b (Hib) Hepatitis B Human papillomavirus Influenza Japanese encephalitis Measles Measles vaccination catch-up guide Meningococcal Mpox (formerly known as monkeypox) Mumps Pertussis Pneumococcal Poliomyelitis Respiratory syncytial virus (RSV) Rotavirus Rubella Varicella-zoster (chickenpox) Zoster (shingles) Injection site reactions Vaccine components Vaccines for Australian adults Vaccinations during pregnancy NCIRS webinar series Patient communication resources Specialist immunisation services SKAI - supporting health professionals NCIRS newsletters Vaccine safety Key points COVID-19 is a disease caused by the SARS-CoV-2 virus
Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website
Top results
COVID-19 vaccines in 2023 - Australian Prescriber
As SARS‑CoV‑2 continues to evolve, vaccines are being updated, and policymakers are reviewing the optimal timing of future booster doses to maintain adequate protection against severe illness, particularly for older adults.
Read more on Australian Prescriber website